The Edoxaban data in acute VTE treatment look pretty good, but Eliquis represents strong competition (#msg-89518539). Note that the primary efficacy endpoint was different.
Xarelto, which is already approved in the US and EU for acute VTE treatment, is also formidable competition.
Market Data 
Markets 
AI
